Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00243659 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

A Phase 3 study of Hemophilia A, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 3
Development phase
30
Enrollment target
17
Study locations

NCT00243659 is a Phase 3 study of Hemophilia A that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 30 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (67% lower). The trial reports 17 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00243659, a Phase 3 study of Hemophilia A, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
30 participants
Enrollment target
17
Study locations

Study Summary

This study will examine the efficacy and safety of ReFacto AF in patients with severe and moderately severe hemophilia A undergoing elective major surgery when administered by either bolus injections (BI) or continuous infusion (CI).

Conditions Studied

Hemophilia A

Interventions

  • BIOLOGICAL ReFacto AF

Study Locations (17)

Other

  • - Perth
  • - Vienna
  • - Budapest
  • - Auckland
  • - Chirstchurch
  • - Warsaw
  • - Bucurest
  • - Malmo
  • - Stockholm

Michigan

  • - Detroit
  • - Detroit

Pennsylvania

  • - Hershey
  • - Pittsburgh

California

  • - La Jolla

North Carolina

  • - Chapel Hill

Texas

  • - Houston

Virginia

  • - Charlottesville

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2006-04
Est. Completion 2008-06
Phase Phase 3

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00243659

The ClinicalTrials.gov registry entry for NCT00243659 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (67% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which ReFacto AF is the first listed.

NCT00243659 reports 17 study locations spanning 7 distinct geographic areas - top geographies include Other, Michigan, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00243659 about?

NCT00243659 is a clinical study titled "Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery". This study will examine the efficacy and safety of ReFacto AF in patients with severe and moderately severe hemophilia A undergoing elective major surgery when administered by either bolus injections (BI) or continuous infusion (CI).

What is the current status of trial NCT00243659?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2006-04. Estimated completion is 2008-06.

What conditions does trial NCT00243659 study?

This clinical trial studies the following conditions: Hemophilia A.

What interventions are being tested in trial NCT00243659?

The interventions under investigation include: ReFacto AF (BIOLOGICAL).

Who is sponsoring clinical trial NCT00243659?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00243659 being conducted?

This trial has 17 study locations across California, Michigan, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hemophilia A

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.